Shari Brazinsky
Pulmonary Disease · San Diego, CANPI 1245339340
Payments from drug & device makers
Across 579 payments — averaging $901.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$254K
- AstraZeneca$83K
- Insmed, Inc.$52K
- Chiesi USA, Inc.$45K
- Roche Products Limited$35K
- Sanofi US Services Inc.$18K
- plus $34K from 39 others
What the payments were for
- Consulting fees$6451%
- Speaking & faculty fees$68,82384%
- Travel & lodging$4,5195%
- Food & beverage$8,02810%
- Education$1710%
- Gifts$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$52,223
- ANORO ELLIPTA$2,400
- BEVESPI AEROSPHERE$1,289
- ZERBAXA$114
- DUPIXENT$114
How this compares
$522,000 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in San Diego
- Edward FedermanSan Diego$3.6M
- David PochSan Diego$1.5M
- Samir MakaniSan Diego$371K
- George ChengSan Diego$309K
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Aaron WeinbergIrvine$5.1M
- Michael RothLos Angeles$4.5M
- Namita SoodSacramento$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.